In this issue:
PSA screening and long-term mortality in prostate cancer
Consumer feedback on the 2016 Australian PSA testing guidelines
High FOLH1 RNA expression in prostate cancer
AI for prediction of long-term outcomes in high-risk prostate cancer
OS with 177Lu-PSMA-617 vs change of ARPI in mCRPC
Ten-year survival rates by PSA nadir in mHSPC
AI for streamlining MDT recommendations
Updated PSMA-PET prostate cancer risk groups
ADT + metastasis-directed therapy for oligometastatic prostate cancer
Intraductal carcinoma of the prostate with no PSMA-PET uptake pattern
Please login below to download this issue (PDF)